When looking at the LIN28-regulated oncogenes, analyses of CRISPR-engineered cells suggest that the LIN28/let-7 axis regulates MYC and cell cycle pathways in multiple myeloma and provides proof of principle for therapeutic regulation of MYC through let-7. Here, MYC is linked to plasma cell myeloma.